Yasemin ZER, Nazan BAYRAM, İclal BALCI, Ayten FİLİZ

Investigation of the causative agents for community-acquired pneumonia in adult patients

Community-acquired pneumonia (CAP) is a common condition in healthy people, causing morbidity and mortality worldwide despite latest advances in therapy and immunization procedures. Causative agents cannot be detected in approximately 50% of CAP episodes and therapy is initiated empirically. We aimed to determine the spectrum and frequency of the causative agents in patients with CAP in a university hospital. Materials and methods: Seventy seven adult patients hospitalized with CAP from November 2007 to March 2008 were included. CAP was diagnosed with clinical, radiological, and laboratory signs. Results: Sputum and blood cultures grew Streptococcus pneumoniae in 15 specimens; Haemophilus influenzae in 4, Klebsiella pneumoniae in 4, Staphylococcus aureus in 3, and Escherichia coli in 2. Mycoplasma pneumoniae DNA was detected in serum from 10 patients with RT-PCR. Legionella pneumophila urinary antigen was detected in 5 patients. Serological IgM antibodies to Chlamydia pneumoniae in 7 patients and Respiratory Syncytial Virus in 2 patients were observed. Etiology was not determined in 32.5% of patients. The most frequently identified pathogens causing CAP were S. pneumoniae, M. pneumoniae, and C. pneumoniae in descending order in our hospital. Conclusion: Although determination of causative agents in all CAP patients has not been accomplished, knowledge of the spectrum and frequency of local causative agents are valuable for targeted therapy.

Anahtar Kelimeler:

Key words: Community-acquired pneumonia, sputum cultures, S. pneumoniae, M. pneumoniae

Investigation of the causative agents for community-acquired pneumonia in adult patients

Keywords:

Key words: Community-acquired pneumonia, sputum cultures, S. pneumoniae, M. pneumoniae,

PDF

___

Acar A, Öncül O. Toplum Kökenli Pnömoniler. Klimik Derg 2007; 20(1): 3-16.
Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community- acquired pneumonia: an evidence based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000; 31: 387-421.
Restrepo MI, Anzueto A. Guidelines for the diagnoses and treatment of adult lower respiratory tract infections: a true “European cooperative effort”. Eur Respir J 2005; 26: 979-81.
Ruiz M, Ewig S, Torres A, Arancibia F, Marco F, Mensa J, et al. Severe community-acquired pneumonia: risk factors and follow-up epidemiology. Am J Respir Crit Care Med 1999; 160: 923-9.
Tabak F. Toplum kökenli pnömonilerde laboratuvar yöntemlerinin akılcı kullanımı. Ankem Derg 2005; 19(2): 24-7.
Metlay JP, Fine MJ. Testing strategies in the initial management of patients with community-acquired pneumonia. Ann Intern Med 2003; 138: 109-18.
Almirall, Bolibar I, Toran P, Pera G, Boquet X, Balanzo X, Sauca G. Contrubition of C-reaktive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 2004; 125: 1335-42.
Garcia-Vazquez E, Marcos MA, Mensa J, Roux de A, Puig J, Font C, et al. Assesment of the usefulness of sputum culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system. Arc Intern Med 2004; 164: 1807-11.
Roson B, Carratala J, Verdaguer R, Dorca J, Manresa F, Gudiol F. Prospective study of the usefulness of sputum gram-stain in the initial approach to community-acquired pneumonia requiring hospitalization. Clin Infect Dis 2000; 31: 869-74.
Küçükardalı Y, Öncül O, Nalbant S, Çankır Z, Top C, Ağdaş Ş, et al. Yaşlı popülasyonda toplum kökenli pnömoni olguları. Geriatri 2001; 4(2): 59-62.
Kömürcüoğlu B, Büyükşirin M, Çıkırıkçıoğlu B, Öztuna I, Perim K. 60 yaş ve üzeri hastalarda toplum kökenli pnömonilerin genel özellikleri. Solunum Derg 2000; 2: 80-4.
Fidan A, Kıral N, Erdem İ, Eren A, Saraç G, Çağlayan B. Toplum kökenli pnömonilerde hastane mortalitesi ve ulusal pnömoni tanı ve tedavi rehberlerine göre değerlendirme. Toraks Derg 2005; 6(2): 115-21.
Yüce A, Yapar N. Mycoplasma türleri. In: Willke Topçu A, Söyletir G, Doğanay M. Editors. İnfeksiyon Hastalıkları ve Mikrobiyolojisi. 1st ed. İstanbul:Nobel Tıp Kitabevleri; 2002. p. 1453-9.
Özlü T, Bülbül Y, Kaygusuz S, Öztuna F, Yıldırım Z, Köksal İ. Toplum Kökenli Pnömoni Olgularımızda M. pneumoniae, C. pneumoniae ve L. pneumophilia Sıklığı. Solunum Hastalıkları 2000; 11: 135-9.
Esposito S, Blasi F, Bellini F, Allegra L, Principi N, Mowgli Study Group. Mycoplasma pneumoniae and Chlamydia pneumoniae infections in children with pneumonia. Eur Respir J 2001, 17: 241-5.
Harris JS, Kolokathis A, Campbell M, Cassell GH, Hammerschlag MR. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. Pediatr Infect Dis J 1998; 17: 865-71.
Principi N, Esposito S. Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients. Drug Safety 1999; 20: 25-41.
Cunha BA. Ambulatory community-acquired pneumonia: the predominance of atypical pathogens. Eur J Clin Microbiol Infect Dis 2003; 22: 579-83.
Bohte R, Van Furth R, Van Der Broek PJ. Aetiology of community acquired pneumonia: a prospective study among adults requiring admission to hospital. Thorax 1995; 50: 543-7.
Ruiz M, Ewing S, Marcos MA, Martinez JA, Arancibia F, Mensa J, et al. Etiology of community acquired pneumonia: impact of age, comorbidity, and severity. Am J Respir Crit Care Med 1999; 160: 397-405.
Neill AM, Martin IR, Weir R, Anderson R, Chereshsky A, Epton MJ, et al. Community acquired pneumonia: Aetiology and usefulness of severity. Thorax 1996; 51: 1010-6.